ACCESSWIRE
United States
Tel: 1-888-952-4446
Website: https://www.accesswire.com/
Email: DigitalSales@accesswire.com
About ACCESSWIRE
ACCESSWIRE is a global newswire and communications network, delivering regional, national and international news to thousands of customers across the world. ACCESSWIRE serves both public and private companies, disseminating their full-text and rich media press releases to news media, financial markets, investors, information websites, databases, bloggers and social networks.
The press release platform offers an exceptionally cost-effective Fair Disclosure, Regulation FD news dissemination and media outreach service.
Platform users can easily publish rich media assets, such as video, audio and images, and build their own distribution to the most-needed outlets. Users can effectively distribute an earnings announcement, product launch, community message, M&A transaction or corporate update to the worldwide news network.
Corporate issuers and their constituents find the cloud-based platforms and related services particularly robust — from document creation through dissemination to regulatory bodies, platforms and shareholders.
Contact ACCESSWIRE’s parent company, Issuer Direct, to learn more.
6081 articles about ACCESSWIRE
-
Utah Medical Products, Inc. Announces Special Dividend - Nov 02, 2021
11/2/2021
Utah Medical Products, Inc. announces that its Board of Directors approved a special cash dividend of two dollars per share of common stock payable on December 29, 2021 to stockholders of record at the close of business on December 15, 2021.
-
Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/2/2021
Company To Host an Investor Conference Call on Tuesday, November 2, 2021 at 8:00 AM EDT
-
CB Scientific Announces Addition of Brooke Martellaro as Chief Financial Officer
11/2/2021
CB Scientific. Inc. is a provider of remote ECG cardiac monitoring products and services; simple wearable solutions for detecting potentially life-threatening heart arrhythmias in patients with heart-related issues, both domestically and internationally.
-
Angle PLC Announces Change of Adviser
11/2/2021
ANGLE plc, a world-leading liquid biopsy company, is pleased to announce the appointments of Berenberg as its Nominated Adviser and Joint Broker and Jefferies as its Joint Broker with immediate effect.
-
The Merger of Dragon SPAC S.p.A. and Napo EU S.p.A. has Closed
11/1/2021
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the merger of its Italian subsidiary Napo EU S.p.A. and Dragon SPAC S.p.A. has closed.
-
Apollo Endosurgery Announces Publication of a Multicenter Study of Its X-Tack(R)Endoscopic HeliX Tacking System
11/1/2021
Apollo Endosurgery, Inc. announced the publication of a multi-center study of the X-Tack System in closing challenging gastrointestinal defects.
-
Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation
11/1/2021
ImmunoEngineering Inc. today announced a keynote presentation delivered on Friday, October 29, at the "Materials in the Anthropocence" Conference in Michoacán, México.
-
NLS Pharmaceutics CEO Issues Letter to Shareholders
11/1/2021
NLS Pharmaceutics Ltd. announces that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders
-
Apollo Endosurgery, Inc. Reports 28% Revenue Growth in Third Quarter Conference Call and Webcast to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET
11/1/2021
Apollo Endosurgery, Inc., a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced financial results for the third quarter ended September 30, 2021 and recent corporate highlights.
-
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
11/1/2021
Lexaria Bioscience Corp. has commenced an important new study exploring whether DehydraTECH TM -CBD evidences superior ability to inhibit seizure activity
-
Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer’s Disease
11/1/2021
Halberd Corporation (OTC PINK:HALB) successfully eradicated 100% of IL-6 from synthetic cerebral spinal fluid (CSF) in preliminary testing.
-
Biophytis to Report Restated Financial Statements for Previous Periods and as of June 30, 2021
10/29/2021
Biophytis SA reports the restated financial statements as per the Company's previous announcement on October 7, 2021 for the periods ending December 31, 2019, December 31 2020, June 30 2020 and June 30 2021, with no impact on the Company's cash and cash equivalent as of June 30 2021.
-
Polyphor Shareholders Approve All Resolutions for the Planned Merger with EnBiotix at the Extraordinary General Meeting
10/29/2021
Polyphor AG announced that its shareholders approved all proposals of the Board of Directors at the Extraordinary General Meeting on October 28, 2021, with a significant majority.
-
Invitation to Presentation of BioInvent’s Interim Report January–September 2021
10/28/2021
BioInvent International AB invites to a presentation of the third quarter report 2021 and a telephone conference with CEO Martin Welschof.
-
Viveve Announces Issuance of New Device and Methods Patent in U.S
10/28/2021
Viveve Medical, Inc., a medical technology company focused on women's intimate health, announced that the United States Patent and Trademark Office recently issued U.S. Patent No. 11,154,349.
-
Sanara MedTech Inc. Announces Third Quarter 2021 Earnings Release and Conference Call Dates
10/28/2021
Based in Fort Worth, Texas, Sanara MedTech Inc., a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced details for the release of its results for the third quarter ended September 30, 2021.
-
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8th, 2021
10/28/2021
Amphastar Pharmaceuticals, Inc. announced that the Company will release results for its third quarter of 2021 ended September 30, 2021, after the market closes on Monday, November 8, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
-
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
10/28/2021
RepliCel Life Sciences Inc., a company developing next-generation technologies in aesthetics and orthopedics, announced the DermaPrecise trademark for its dermal injector product portfolio.
-
EV Biologics Chief Medical Officer Publication on COVID-19 & Exosomes
10/28/2021
EV Biologics Corp, OTC Pink:YECO, updated shareholders about a recent publication authored by its Chief Medical Officer, Dr. Jason Sanders.
-
CB Scientific, Inc. Appoints Paul Danner as Chairman
10/28/2021
CB Scientific, Inc. is a provider of remote ECG cardiac monitoring products and services; simple wearable solutions for detecting potentially life-threatening heart arrhythmias in patients with heart-related issues, both domestically and internationally.